Updates are taking place with the Zander Therapeutics(Entest-ENTB) website. See below:
Bone Marrow and Aplastic Anemia Therapy
A personalized cellular therapeutic product designed to stimulate blood production in veterinary patients whose bone marrow is not properly functioning.
•Fat stem cell-based product to treat bone marrow that has been damaged
•Bone marrow damage occurs from radiation, chemotherapy or chronic conditions
•Uses animal’s own fat as a source of endothelial cells to heal damaged bone marrow
•Toxicity studies have been successfully completed by Regen BioPharma Inc., the licensor of this technology to Zander Therapeutics.
•Aims to provide “natural” replacement to synthetic cytokines.
For cats and dogs, Zander will target:•Arthritis
•Cancer
•Autoimmune Disorders
•Feline Leukemia
For horses, Zander will target:•Exercise Induced Pulmonary Hemorrhage (EIPH)
United States Food and Drug Administration (FDA) Investigational New Drug Application (IND #15376, status cleared for use in humans by Regen BioPharma Inc. -- licensor to Zander Therapeutics Inc.)
Small Molecule Targeting Cancer Stem Cell Genes
Small Molecule targeting of the cancer stem cell is the process of “coaxing” the cancer stem cell to turn into a normal cell. Regen BioPharma (licensor) has identified and filed patents on a novel gene controlling the process of cancer stem cell differentiation.
•Objective is to identify small molecules that can induce differentiation of cancer stem cells
•High through-put screening identified 7 “hit” compounds
•Currently in pre-clinical development
•Additional indications include solid tumors and acute leukemia
Products in Development
•?ZT 396 is an NR2F6 stimulator for exercise induced pulmonary hemorrhage (equine)
•ZT 430 is an NR2F6 stimulator for arthritis and autoimmunity (feline & canine)
•ZT 240 is an NR2F6 inhibitor for canine cancer (lymphoma)
•ZT 110 is an NR2F6 inhibitor feline leukemia
2017 has to be the year.IMO. GL.
